This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a preclinical study for their nasal anti-CD3 treatment, foralumab, which could provide a novel solution for long COVID.

By studying the effects of the nasal anti-CD3 in a mouse model of TBI, researchers found the spray could reduce damage to the central nervous system and behavioral deficits, suggesting a potential ...

“Our positive results in animals with ongoing disease raise the possibility that oral anti-CD3 antibodies might be an effective immunomodulatory therapy for SLE that could be easily and rapidly ...

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with ...

Anti-CD3 monoclonal antibody treatment to inhibit activated T cells holds promise; however, adverse effects associated with cytokine release are common. Visilizumab—humanized and modified anti ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor ...

Conventionally, the first and second stimulation signals in vitro, simulating the process in vivo, are achieved using anti-CD3 antibody, anti-CD28 antibody, or CD3/CD28 magnetic beads, along with the ...

Researchers at Mass General Brigham found that a nasal spray delivering anti-CD3 (Foralumab) reduces neuroinflammation, limits central nervous system damage and improves behavioral outcomes in mice ...